சாம் ஸ்யாக்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from சாம் ஸ்யாக்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In சாம் ஸ்யாக்ஸ் Today - Breaking & Trending Today
Protagonist Therapeutics Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA 2021 Updated Phase 2 analysis to be presented by Dr. Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai News provided by Share this article Share this article NEWARK, Calif., May 12, 2021 /PRNewswire/ Protagonist Therapeutics ( Protagonist or the Company ) (Nasdaq: PTGX), today announced that an abstract highlighting updated data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera ( PV ) has been selected for an oral presentation at the upcoming European Hematology Association ( EHA ) 2021 Annual Congress. The EHA Congress will take place virtually June 9-17, 2021. Rusfertide, a synthetic, injectable hepcidin mimetic, regulates iron homeostasis and controls the absorption, storage, and distribution of iron in the body. Rusfertide was discovered through the Co ....
Protagonist Therapeutics (PTGX) Announces Presentation of Updated Results from Phase 2 Study of Rusfertide in Polycythemia Vera, Selected for Oral Presentation at EHA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Protagonist Therapeutics Completes Enrollment for Phase 2 Study of Rusfertide in Polycythemia Vera and Announces Plans for Data Update at an Upcoming Medical Meeting Rapid completion of Phase 2 enrollment signals further momentum for the development of rusfertide in polycythemia vera News provided by Share this article Share this article NEWARK, Calif., April 27, 2021 /PRNewswire/ Protagonist Therapeutics, Inc. ( Protagonist or the Company ) (Nasdaq: PTGX), today announced the completion of enrollment for the Company s Phase 2 study of rusfertide (PTG-300) in polycythemia vera ( PV ). Enrollment easily exceeded the targeted 50 evaluable patients for the study. Those patients eligible for enrollment, but unable to participate in the Phase 2 study, will have the opportunity to enroll in the planned upcoming Phase 3 study, which was announced in March 2021. ....
On Jan. 11, Maricopa County announced those aged 75 and older were eligible to receive a COVID-19 vaccine. But the gulf between availability of the vaccine and the ability to ....